Galapagos To Buy Inpharmatica

Galapagos NV (Euronext & AIM: GLPG) has agreed to acquire Inpharmatica Ltd., a UK-based provider of genome-scale predictive products and services for drug discovery research. The total deal is valued at up to Euro 19.1 million, including a Euro 6.5 million upfront cash payment. Inpharmatica has raised around $75 million in VC funding since 1998, from firms like 3i Group, Abingworth Management, Advent Venture Partners, August Equity, GIMV, Gilde, Reed Elsevier Ventures, Unibio Ltd., Genentech and Vertex Management.